The 1. StatusmeetingiRhythmics takes place at the 10.03.2020
Department Life, Light & Matter
Research building LL & M
Albert-Einstein-Str. 25, 18059 Rostock
More information soon.
Prof. Dr. rer. nat. Robert David, Koordinator iRhythmics
Professor für Regenerative Medizin in der Herzchirurgie der Universitätsmedizin Rostock
Phone: +49-381 498 8973
Dr. Anna Skorska, Projektmanagerin iRhythmics
Wissenschaftliche Mitarbeiterin firstname.lastname@example.org
Phone: +49-381 498 8974 // -381 494 6105
01. Oct. 2018 -
30th Sep 2021
LaGuS M / V, ESF
Community project with the
Institute for Experimental Gene Therapy and Tumor Research
"Development & Application of Optimized Cardiospecific AdVector-Based Systems for In Situ Establishment of a Biological Pacemaker"
Project Manager Prof. Dr. med. Robert David, Prof. Dr. med. Brigitte M. Pützer
01. Oct. 2018 -
30th Sep 2020
DA 1296 / 6-1
funded by DFG
"programmed sinus node tissue for therapy and test systems - iSAB"
"stem cell-activated pacemaker cells for in vivo and in vitro use"
Project leader: Prof. dr. Gustav Steinhoff, Prof. dr. Robert David
01. May 2016 -
Dec. 31, 2019
03 VP 00 241
funded by BMBF
Joint research project „Added value in regenerative medicine – a pioneering approach to facilitate translation“
The foundation of the RTC is based on the joint research project “Added value in regenerative medicine”which is funded for four years. It has two goals:
1) Fostering the continued development of cardiac stem cell therapies so that they can be applied as standardised treatments of high quality to patients showing appropriate indications. This requires proof of efficacy and safety of the therapy in accordance with all relevant regulations and guidelines by means of clinical studies and parallel research projects.
2) Standardisation of the translational process. According to the latest legal situation, treatments with stem cells belong to the “Advanced Therapy Medicinal Product ”. The essential transfer process from basic research to the launch of stem cell therapy as a novel drug or treatment method ( translation) is virgin territory for scientists, as well as industry and licensing authorities. Using the example of cardiac stem cell therapy, the RTC will work closely with all relevant authorities to define standards which offer a maximun of quality and safety for patients. In addition, information regarding the translational process will be made available (link zu Translation). Further research and development projects in the field of regenerative medicine will directly benefit from the accumulated know-how and technologies. The RTC will offer trainings and seminars for prospective users of the standardised stem cell therapies.